HHS pursues development of single dose nasal spray anthrax vaccine

For the first time, one of the USA’s Centers for Innovation in Advanced Development and Manufacturing (CIADM) will support development of a second-generation anthrax vaccine under a task order issued by the US Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR).

The CIADM led by the Texas A&M University System in College Station, Texas, will begin advanced development and manufacturing activities for the investigational vaccine under an 18-month, $10.49 million task order from the ASPR’s Biomedical Advanced Research and Development Authority (BARDA).

The investigational anthrax vaccine, dubbed NasoShield, is being developed to be administered as a nose spray and to require only a single dose to protect against infections caused by inhalation anthrax.